Malignant Fibrous Histiocytoma and Undifferentiated Pleomorphic Sarcoma A Retrospective Single-Center Analysis (1994–2022)
Öz
Background: Malignant Fibrous Histiocytoma (MFH), reclassified as undifferentiated pleomorphic sarcoma (UPS) in the 2013 World Health Organization (WHO) classification, is a high-grade pleomorphic sarcoma of mesenchymal origin. It is the most common soft-tissue sarcoma in late adulthood, predominantly affecting males aged 40-80. Surgical resection remains the cornerstone of treatment, while radiotherapy (RT) and chemotherapy (CT) are used selectively to improve local control and survival. This study evaluated the prognostic impact of surgical margin status and adjuvant treatments.
Methods: This retrospective study evaluated 57 patients with MFH/UPS (31 males, 26 females) treated and followed between 1994 and 2022. All patients underwent surgical intervention, and those developing local recurrence were treated with second or third surgical procedures when feasible. Surgical margin status (R0, R1, R2) and its association with local recurrence and distant metastasis were analyzed.
Results: Negative surgical margins (R0 resection) achieved during the initial surgery were strongly associated with improved local disease control. Positive surgical margins (R1/R2) were significantly associated with the development of lung metastases. Repeated surgeries and adjuvant therapies were insufficient to compensate for inadequate initial surgical margins.
Conclusions: Achieving wide, margin-negative resection at the initial surgical intervention is the most critical determinant of oncologic outcome in MFH/UPS. While RT and CT may provide adjunctive benefits in selected cases, optimal surgical management remains the key factor for long-term disease control.
Anahtar Kelimeler
Malignant Fibrous Histiocytoma, Undifferentiated Pleomorphic Sarcoma, Soft Tissue Sarcoma, Surgical Margin, Local Recurrence, Chemotherapy, Radiotherapy.
Destekleyen Kurum
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Etik Beyan
Ethical approval for this retrospective study was obtained from the Non-Interventional Clinical Research Ethics Committee of SBÜ Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital (Approval No: 2025-09/132; Date: 02 October 2025). The study was conducted in accordance with the principles of the Declaration of Helsinki. Given the retrospective nature of the analysis and the use of de-identified archival data, the requirement for individual written informed consent was waived by the Ethics Committee.
Teşekkür
The authors would like to thank the staff of the Orthopedics and Traumatology Clinic of Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital for their support during data collection and patient follow-up.
Kaynakça
- Campanacci M. Bone and Soft Tissue Tumors. Bologna: Rizzoli Orthopaedic Institute; 1990.
- Simon MA, Springfield DS. Surgery for Bone and Soft Tissue Tumors. Philadelphia: Lippincott-Raven; 1998.
- Salo JC, Lewis JJ, Woodruff JM, Brennan MF. Malignant fibrous histiocytoma of the extremity. Cancer. 1999;85:1765-72.
- Rosenberg AE. Malignant fibrous histiocytoma: past, present and future. Skeletal Radiol. 2003;32:613-8.
- Bertoni F, Capanna R, Biagini R. Malignant fibrous histiocytoma of soft tissue: analysis of 78 cases located deeply in the extremities. Cancer. 1985;56:356-67.
- Kearney MM, Soule EH, Ivins JC. Malignant fibrous histiocytoma: a retrospective study of 167 cases. Cancer. 1980;45:167-78.
- Weiss SW, Enzinger FM. Malignant fibrous histiocytoma: an analysis of 200 cases. Cancer. 1978;41:2250-66.
- Belal A, Kandil A, Allam A, et al. Malignant fibrous histiocytoma: a retrospective study of 109 cases. Am J Clin Oncol. 2002;25:16-22.
- Trojani M, Contesso G, Coindre JM, et al. Soft tissue sarcomas of adults: study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer. 1984;33:37-42.
- Pezzi CM, Rawlings MS, Esgro JJ, et al. Prognostic factors in 227 patients with malignant fibrous histiocytoma. Cancer. 1992;69:2098-103.